Open Access. Powered by Scholars. Published by Universities.®
- Institution
Articles 1 - 2 of 2
Full-Text Articles in Cardiology
A Review Of Bleeding Risk With Impella-Supported High-Risk Percutaneous Coronary Intervention, George W. Vetrovec, Amir Kaki, Thom G. Dahle
A Review Of Bleeding Risk With Impella-Supported High-Risk Percutaneous Coronary Intervention, George W. Vetrovec, Amir Kaki, Thom G. Dahle
Articles
Complex, high-risk percutaneous coronary intervention (HR-PCI) is increasingly being performed, often with mechanical circulatory support (MCS), though to date, there are limited randomised data on the efficacy of MCS for HR-PCI. The majority of MCS is provided by intra-aortic balloon pumps, but increasingly Impella® (Abiomed, Danvers, MA, USA) heart pumps are being used. While the Impella pumps provide greater increases in cardiac output, these devices require large bore access, which has been associated with an increased risk of bleeding and vascular complications. Decisions regarding the use of Impella are often based on risk–benefit considerations, with Impella-related bleeding risk being a …
Outcomes Of Mechanical Circulatory Support For Giant Cell Myocarditis: A Systematic Review, Preeyal M. Patel, Abhiraj Saxena, Chelsey T. Wood, Mfa, Thomas J. O'Malley, Elizabeth Maynes, John W..C. Entwistle, H. Todd Massey, Preethi R Pirlamarla, René J Alvarez, Leslie T Cooper, J. Eduardo Rame, Vakhtang Tchantchaleishvili
Outcomes Of Mechanical Circulatory Support For Giant Cell Myocarditis: A Systematic Review, Preeyal M. Patel, Abhiraj Saxena, Chelsey T. Wood, Mfa, Thomas J. O'Malley, Elizabeth Maynes, John W..C. Entwistle, H. Todd Massey, Preethi R Pirlamarla, René J Alvarez, Leslie T Cooper, J. Eduardo Rame, Vakhtang Tchantchaleishvili
Division of Cardiology Faculty Papers
Treatment of giant cell myocarditis (GCM) can require bridging to orthotopic heart transplantation (OHT) or recovery with mechanical circulatory support (MCS). Since the roles of MCS and immunotherapy are not well-defined in GCM, we sought to analyze outcomes of patients with GCM who required MCS. A systematic search was performed in June 2019 to identify all studies of biopsy-proven GCM requiring MCS after 2009. We identified 27 studies with 43 patients. Patient-level data were extracted for analysis. Median patient age was 45 (interquartile range (IQR): 32–57) years. 42.1% (16/38) were female. 34.9% (15/43) presented in acute heart failure. 20.9% (9/43) …